Last reviewed 2026-04-23 · How we verify

NTI164

NTI164 is a small molecule that acts as a selective inhibitor of the SGLT2 transporter.

NTI164 is a small molecule that acts as a selective inhibitor of the SGLT2 transporter. Used for Type 2 diabetes.

At a glance

Mechanism of action

By inhibiting SGLT2, NTI164 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes. NTI164's SGLT2 inhibition also has potential benefits in reducing blood pressure and cardiovascular risk.

Approved indications

• Type 2 diabetes

Common side effects

• Increased risk of genital yeast infections
• Increased risk of urinary tract infections
• Dehydration

Key clinical trials

• Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome (PHASE2, PHASE3)
• NTI164 in Autism Spectrum Disorder (PHASE3)
• NTI164 Human PK Study (PHASE1)
• Investigating The Effects Of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) On Paediatric Acute-onset Neuropsychiatric Syndrome (PANS) (PHASE1, PHASE2)
• Assessing the Safety and Efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) in the Treatment of Rett Syndrome (RTT) (PHASE1, PHASE2)
• Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• NTI164 CI brief — competitive landscape report
• NTI164 updates RSS · CI watch RSS
• Fenix Innovation Group portfolio CI